XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Aqneursa

October 5, 2026

IntraBio Announces U.S. FDA Approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia

AUSTIN, Texas–(BUSINESS WIRE) September 18, 2026 –IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the U.S. Food and Drug… Source: Read More

FDA Acceptance

Aqneursa, Ataxia-Telangiectasia, FDA Approval, IntraBio, levacetylleucine

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

30 DAY

60 DAY

90 DAY

120 DAY

UNLIMITED

Get FREE Biotech Stock Catalyst Reports

Email